)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Aurinia Pharmaceuticals (AUPH) investor relations material
Aurinia Pharmaceuticals Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary31 Jul, 2025
Executive summary
Total revenue and net product sales for Q2 and six months ended 06/30/2025 increased 22% and 23% year-over-year, driven by LUPKYNIS/Loop Kinus sales and expanded market penetration.
Net income for Q2 2025 was $21.5M ($0.16 EPS), up from $0.7M in Q2 2024; six-month net income was $44.9M ($0.33 EPS), versus a $10M loss last year.
Positive Phase 1 results for aritinercept/Aratinacept, with plans to initiate further clinical studies in at least two autoimmune diseases in H2 2025.
Strategic restructuring in 2024 led to significant cost reductions and a sharpened focus on LUPKYNIS and aritinercept development.
Growth in LUPKYNIS sales attributed to updated treatment guidelines recommending its use as first-line therapy and increased adoption in rheumatology and hospital settings.
Financial highlights
Q2 2025 total revenue was $70M, up from $57.2M in Q2 2024; six-month revenue was $132.5M, up from $107.5M year-over-year.
Net product sales of LUPKYNIS/Loop Kinus were $66.6M for Q2 and $126.5M for six months, up 21% and 23% year-over-year.
Cash flow from operations for six months was $45.5M, compared to negative $2.8M in 2024; adjusted for restructuring, cash flow was $57M.
Cash, equivalents, and investments totaled $315.1M as of 06/30/2025, down from $358.5M at year-end 2024, reflecting share repurchases.
Operating expenses for Q2 and six months were $49.9M and $90.5M, down from $58.7M and $122.3M in 2024, mainly due to restructuring.
Outlook and guidance
Full-year 2025 total revenue guidance raised to $260M–$270M (from $250M–$260M); net product sales guidance raised to $250M–$260M (from $240M–$250M).
Guidance reflects historical seasonality and potential for continued growth in Q3 and Q4.
The company expects to fund future operations with existing cash and cash generated from operations.
SG&A expenses are expected to remain lower in 2025 due to restructuring, while R&D expenses are anticipated to increase.
Plans to initiate clinical studies for aritinercept in at least two autoimmune diseases in H2 2025.
AUR200 indication disclosure triggers
LUPKYNIS growth drivers for raised guidance
Share buyback strategy vs. rising R&D costs
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Aurinia Pharmaceuticals earnings date
Q3 20256 Nov, 2025
Next Aurinia Pharmaceuticals earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Aurinia is a biopharmaceutical company driven by a relentless commitment to bring life-changing therapies, like voclosporin, to patients suffering from diseases with high unmet medical need. The Company’s lead product, voclosporin, is being investigated as a therapy for LN. The Company is initially targeting LN and has plans to study additional disease indications. The company is headquartered in Victoria, Canada.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage